Compare Recursion Pharmaceuticals Inc (RXRX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Stryker Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Stryker Corporation is far larger — about 80× Recursion Pharmaceuticals Inc's market cap, and Stryker Corporation pays a 1% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SYK | |
|---|---|---|
Market Cap | $1.53B | $122.35B |
Sector | Health | Technology |
52-Week High | $6.79 | $403.53 |
52-Week Low | $2.84 | $282.58 |
Enterprise Value | $946.50M | $134.10B |
Dividend Yield | — | 1% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
